Explore By Subject Area   

Lead Editorial

Morphic Therapeutic’s Acquisition by Eli Lilly From the CMO Perspective

Morphic Therapeutic’s Acquisition by Eli Lilly From the CMO Perspective

In July 2024, Eli Lilly acquired Morphic Therapeutic for $3.2B. Former Morphic Therapeutic CMO Simon Cooper, MBBS, now CMO of LifeMine Therapeutics, shares his experience through the M&A process and offers advice for Biotech CMOs in M&A and partnership conversations within their own organizations.

Read More

More Related Content

Editorial

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.